CN104758285A - Novel compound anti-hypertensive drug - Google Patents
Novel compound anti-hypertensive drug Download PDFInfo
- Publication number
- CN104758285A CN104758285A CN201410003392.7A CN201410003392A CN104758285A CN 104758285 A CN104758285 A CN 104758285A CN 201410003392 A CN201410003392 A CN 201410003392A CN 104758285 A CN104758285 A CN 104758285A
- Authority
- CN
- China
- Prior art keywords
- nitrendipine
- novel compound
- metoprolol
- drug
- hypertensive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a compound preparation used for treating hypertension, particularly a novel compound anti-hypertensive drug which comprises 5-20 mg of nitrendipine and 5-50 mg of metoprolol. The novel compound anti-hypertensive drug solves the problem that when nitrendipine and metoprololare are clinically used at present, side effects are obviously increased to guarantee the curative effect by increase of drug dose since only one of nitrendipine and metoprololare is put into use. According to the novel compound preparation, nitrendipine and metoprololare are used together to achieve synergetic and complementary curative effects; and the novel compound anti-hypertensive drug increases the tolerance of patients, improves the compliance, is reduced in dose to relieve adverse reaction, and is convenient to take and low in price.
Description
Technical field
The present invention relates to medical art, disclose a kind of new compound antihypertensive drug.
Background technology
Hypertension is modal cardiovascular disease, is the great public health problem in global range.About there are 100,000,000 hypertensive patients in China at present.Epidemiological study result display in 1991, China's city and country hypertension awareness is respectively 36% and 13%, and treatment rate is respectively 17% and 5%, and the form of hypertension prevention and control is quite severe.According to WTO prediction, will account for 79% of China's cause of death to the year two thousand twenty noninfectious, its cardiovascular disease will account for first place.
Conventional treatment hypertension drug has calcium antagonist nitrendipine and beta-blocker metoprolol.
Nitrendipine (Nitrendipine), chemistry 2,6-dimethyl-4-(3-nitrobenzophenone)-Isosorbide-5-Nitrae-dihydro-3,5-pyridinedicarboxylic acid methyl ethyl ester by name, molecular formula is C
18h
2oN
2o
6, molecular weight: 360.37, shown in structural formula:
Nitrendipine structural formula
Nitrendipine is a kind of bihydropyridine type calcium antagonist, and this product cardioselective is high, expansible coronary artery and peripheral blood vessel, rapid-action, safety, gentleness, lasting; Lessly there is water-sodium retention, can myocardial oxygen consumption be reduced, to ischemic myocardium, there is protective effect; Reflexive increased heart rate can be there is, without postural hypotension time heavy dose of; Long-term taking curative effect does not subtract, without cumulative action.
Metoprolol (Hydrochlorothiazide), chemistry 1-isopropylamino-3-[p-(2-methoxyethyl) phenoxy group]-2-propanol L (+)-tartrate by name, molecular formula is (C
15h
25nO
3)
2c
4h
6o
6, molecular weight: 684.82, shown in structural formula:
Metoprolol structural formula
Metoprolol is a kind of based on the medicine of β1-adrenergicreceptor retardation (heart selectivity), is therefore well suited for treatment hypertension and angina pectoris, reduces the incidence rate of myocardial infarction, reduce the mortality rate after myocardial infarction.This product can be used for the tachy-arrhythmia that treating paroxysmal supraventricular tachy-arrhythmia, ventricular arrhythmia, digitalis and catecholamine cause due to the excitement of retardance ectopia cordis pacemaker adrenoreceptor.This product energy antagonism catecholamine effect, can treat the arrhythmia that hyperthyroidism causes.When therapeutic dose, this product is not obvious to the effect of shrinking bronchus and peripheral vessels, and after single cases medication, airway resistance can be increased, but adds and can correct with β1receptor agonist.Be mainly used in maintaining treatment, arrhythmia, hyperthyroidism after treating hypertension, angina pectoris, myocardial infarction.
The medicine of alone a kind of larger dose is treated hypertension and is with sometimes and serves untoward reaction; as blood pressure during single therapy reduces the compensation response triggered; there will be weak, dizzy, drowsiness, tinnitus, Nausea and vomiting, epigastric discomfort, constipation through often after taking medicine; sometimes also there will be the phenomenons such as postural hypotension, muscular spasm, insomnia; although these phenomenons are mostly died away in continuous drug administration process, also inconvenience can be brought to patient.
Goal of the invention
When product of the present invention overcomes and uses now nitrendipine and metoprolol clinically, for ensureing that curative effect increases drug dose during an alone medicine, side effect is caused obviously to increase; During drug combination, because nothing meets the pharmaceutical preparation of drug combination dosage, and use clinical medicine dose inaccurate, affect the defect of curative effect of medication.Nitrendipine and metoprolol two medicine share, and curative effect has collaborative, complementary action; Reduce consumption, alleviate untoward reaction, taking convenience, cheap.
Summary of the invention
The object of the invention is to the defect existed for prior art, provide a kind of compound preparation.
The present invention is achieved by the following technical solutions:
One treats hypertensive compound preparation, the component containing following dosage:
Nitrendipine 5-20mg
Metoprolol 5-50mg
One as technique scheme is preferred, a kind of component for the treatment of hypertensive compound preparation and containing following dosage:
Nitrendipine 10-20mg
Metoprolol 12.5-50mg
Preferably treat hypertensive compound preparation as one, it contains the component of following dosage:
Nitrendipine 10mg
Metoprolol 12.5mg
Preferably treat hypertensive compound preparation as one, it contains the component of following dosage:
Nitrendipine 10mg
Metoprolol 25mg
Beneficial effect of the present invention is: the present invention is that low dose of use in conjunction two kinds of antihypertensive drugs are hypertensive to treat, better than wherein a kind of medicine antihypertensive effect of alone larger dose and untoward reaction is less, the treatment of associating lattice can improve efficacy of antihypertensive treatment, in and the untoward reaction that causes of different pharmaceutical, be applicable to hyperpietic's long-term taking in various degree.
This preparation, except containing except above two kinds of active drug, also contains a certain amount of adjuvant; In pharmacy procedure, the addition of adjuvant can be determined according to actual needs.
The adjuvant that this preparation is conventional has: microcrystalline Cellulose, pregelatinized Starch, low-substituted hydroxypropyl cellulose, silicon dioxide, Pulvis Talci, lactose, dextrin, magnesium stearate, carboxymethylstach sodium, calcium sulfate etc.
Compound preparation of the present invention can have various ways, as dosage forms such as compound nitrendipine tablet-metoprolol tablets (ordinary tablet, slow releasing tablet and other special tablets), compound nitrendipine tablet-metoprolol capsules (conventional capsule, slow releasing capsule and other special capsule preparations).
Embodiment 1
A kind of compound preparation, containing following component:
The present embodiment can be made into compound nitrendipine tablet-metoprolol tablets, and preparation method can adopt the preparation method of common pharmaceutical preparation.
Embodiment 2
A kind of compound preparation, containing following component:
The present embodiment can be made into compound nitrendipine tablet-metoprolol tablets, and preparation method can adopt the preparation method of common pharmaceutical preparation.
Claims (4)
1. treat a hypertensive compound preparation, the component containing following dosage:
Nitrendipine 5-20mg
Metoprolol 5-50mg.
2. the hypertensive compound preparation for the treatment of according to claim 1, is characterized in that compound preparation contains the component of following dosage:
Nitrendipine 10-20mg
Metoprolol 12.5-50mg.
3. the hypertensive compound preparation for the treatment of according to claim 2, is characterized in that compound preparation contains the component of following dosage:
Nitrendipine 10mg
Metoprolol 12.5mg.
4. the hypertensive compound preparation for the treatment of according to claim 2, is characterized in that compound preparation contains the component of following dosage:
Nitrendipine 20mg
Metoprolol 12.5mg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410003392.7A CN104758285A (en) | 2014-01-02 | 2014-01-02 | Novel compound anti-hypertensive drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410003392.7A CN104758285A (en) | 2014-01-02 | 2014-01-02 | Novel compound anti-hypertensive drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104758285A true CN104758285A (en) | 2015-07-08 |
Family
ID=53640619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410003392.7A Pending CN104758285A (en) | 2014-01-02 | 2014-01-02 | Novel compound anti-hypertensive drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104758285A (en) |
-
2014
- 2014-01-02 CN CN201410003392.7A patent/CN104758285A/en active Pending
Non-Patent Citations (3)
| Title |
|---|
| 夏福昌: "美托洛尔联合尼群地平治疗原发性高血压的临床观察", 《中国药房》 * |
| 支世保: "尼群地平联合美托洛尔治疗高血压病疗效观察", 《中国疗养医学》 * |
| 贺朝忠等: "尼群地平与美托洛尔联用治疗老年性高血压病92例疗效观察", 《华夏医学》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MR | Summary of product characteristics | |
| CA2727326A1 (en) | Dronedarone for the prevention of permanent atrial fibrillation | |
| HUE028919T2 (en) | Capsule for the prevention of cardiovascular diseases | |
| JP2016512234A (en) | Pharmaceutical combination preparation | |
| KR20210139293A (en) | Pulmonary Arterial Hypertension and Associated Pulmonary Arterial Hypertension Treatment and Daily Administration | |
| CA2612179A1 (en) | A pharmaceutical composition comprising loratadine and its use to treat patients with upper respiratory mucosal congestion | |
| CN104758285A (en) | Novel compound anti-hypertensive drug | |
| CN101559228A (en) | Pharmaceutical composition for treating chronic stable angina pectoris with hyperlipemia | |
| CN105832731B (en) | It is a kind of to treat medicine of hypertension and preparation method thereof | |
| CN101637442A (en) | Ranolazine oral sustained-release preparation and preparation method thereof | |
| CN103800336A (en) | Composition with anti-thrombus active medicine | |
| CN101756968A (en) | Novel compound antihypertensive drug | |
| Gallelli et al. | Recurrence of atrial fibrillation after switching from brand to generic atenolol | |
| CN102058591A (en) | Levamlodipine and telmisartan compound preparation | |
| JP2017515858A5 (en) | ||
| CN101756972A (en) | Compound antihypertensive medicament | |
| CN101869562B (en) | Levamlodipine compound medicinal preparation | |
| CN103861081A (en) | Perindopril amlodipine tablet and production process thereof | |
| CN1895249A (en) | Compound preparation for treating hypentension | |
| WO2013138602A1 (en) | An iloperidone metabolite for use in the treatment of psychiatric disorders | |
| US8470363B2 (en) | Antihypertensive pharmaceutical composition | |
| CN102258523A (en) | Compound preparation for treating hypertension and its preparation method | |
| CN101756976A (en) | Novel antihypertensive drug | |
| BRPI0617184A2 (en) | delayed-release pralnacasan formulation | |
| CN101269027A (en) | Atenolol sustained-release dropping pill and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150708 |